secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001437749-26-015590
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety
--------------------------------------------------------------------------------

- Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.
- R&D expenses $2.8M (+215% YoY) driven by PH-762 clinical trial, CMC and toxicology costs.
- G&A expenses $1.4M (+39% YoY) on higher employee costs, investor outreach and professional fees.
- PH-762 dose-escalation study (22 patients) complete; final data being analyzed; FDA submission for next steps targeted Q2 2026.
- ATM agreement with H.C. Wainwright in April 2026 allows up to $6.36M in common stock sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/0001437749-26-015590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/phio20260331_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer